Abivax is growing revenue at 35% year-over-year with analyst consensus implying 52% upside to the price target, but cash burn running at -2,327% of revenue and a quality profile below the minimum quality threshold make this a high-risk, speculative situation where the growth must eventually translate into cash economics.
Thesis pillars
- Extreme Cash Burn Value Trap Risk↓Deteriorating
- Strong Revenue Growth 35pct→Stable
- Analyst Sentiment Material Upside↑Improving
- +1 more pillar — see the Why tab for full reasoning
Abivax SA (ABVX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $118.00: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend.
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in... Read more
Sell if holding. Engine safety override at $118.00: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 6.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.35, news boost analyst cluster(8), semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-09-13Recent Developments — Abivax SA
Latest news
- NEWS This Amer Sports Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday — benzinga Sep 10, 2026 positive
- NEWS 10 Health Care Stocks With Whale Alerts In Today’s Session — benzinga Aug 27, 2026 neutral
- NEWS 10 Health Care Stocks Whale Activity In Today’s Session — benzinga Aug 18, 2026 neutral
- NEWS Abivax Completes Pre-New Drug Application Interaction For Obefazimod With FDA To Treat Adults With Moderately To Severel — benzinga Jul 30, 2026 positive
- NEWS 'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre — benzinga Jul 17, 2026 positive
Generated 2026-09-13T09:57:01Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $118.00: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $110.40. Score 6.3/10, moderate confidence.
Take-profit target: $143.55 (+21.0% upside). Prior stop was $110.40. Stop-loss: $110.40.
Quality below floor (4.0 < 4.0).
Abivax SA trades at a P/E of N/A (forward -35.5). TrendMatrix value score: 7.5/10. Verdict: Sell.
14 analysts cover ABVX with a consensus score of 4.3/5. Average price target: $165.
What does Abivax SA do?ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural...
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.